The Lack of Effect of Routine Magnesium Administration on Respiratory Function in Mechanically Ventilated Patients

Dose‐response relationship and time‐course of the effect of inhaled magnesium sulphate on airflow in normal and asthmatic subjects.

“…There is considerable, although not consistent evidence [18,19] of a beneficial effect of intravenous magnesium in acute and stable asthma [11][12][13][14][15][16][17] and it is not clear why magnesium sulphate administered by the inhaled route should not have the same effect. Magnesium is a vasodilator and it is possible that the apparent bronchodilator properties of intravenous magnesium are due to baroreflex sympathetic activation because of vasodilatation and resultant hypotension.…”

“…Benefit from intravenous magnesium in acute and stable asthma has been reported in several uncontrolled [11][12][13][14] and controlled [15][16][17] studies, although not all studies have confirmed this [18,19]. There is much less information available on the effects of inhaled magnesium on the airway, but two studies of single doses of nebulized magnesium have demonstrated protection against bronchoconstriction induced by methacholine and histamine, by the order of a two fold increase in the PD20 for these agents [20,21].…”

The role of magnesium sulfate in the intensive care unit

“…These injuries include stroke, aneurysmal subarachnoid hemorrhage (ASAH), and traumatic brain injuries (Afshari et al, 2013[2]; Akdemir et al, 2009[6]; Bradford et al, 2013[18]; Chan et al, 2005[23]; Chen et al, 2015[25]; Chen and Carter, 2011[27]; Dabbagh et al, 2006[30]; Dorhout Mees et al, 2012[33]; Friedlich et al, 2009[42]; Gao et al, 2013[45]; Gonzalez-Garcia et al, 2012[49]; Hassan et al, 2012[58]; James et al, 2009[69]; Jiang et al, 2017[71]; Johnson et al, 1993[72]; Kahraman et al, 2003[75]; Kidwell et al, 2009[79]; Kumar et al, 2015[85]; Lamers et al, 2003[87]; Lampl et al, 2001[88]; Mirrahimi et al, 2015[107]; Mousavi et al, 2004[109], 2010[110]; Muir and Lees, 1995[112]; Muir et al, 2004[113]; Muroi et al, 2008[114]; Rahimi-Bashar et al, 2017[122]; Rinosl et al, 2013[125]; Saver et al, 2015[132]; Selvaraj and Syed, 2014[136]; Singh et al, 2012[144]; Sleeswijk et al, 2008[146]; Stippler et al, 2006[148]; van den Bergh et al, 2005[156]; van Norden et al, 2005[157]; Veyna et al, 2002[158]; Wang et al, 2012[163]; Westermaier et al, 2010[166]; Wong et al, 2010[171]; Zafar et al, 2014[172]; Zhao et al, 2016[174]; Zhu et al, 2004[175]). …”

“…Effect of MgSO 4 on biomarkers in different neuropathies has been assessed in several studies (Bharosay et al, 2012[14]; Chan et al, 2005[23]; Friedlich et al, 2009[42]; Gao et al, 2013[45]; Gonzalez-Garcia et al, 2012[49]; Hassan et al, 2012[58]; James et al, 2009[69]; Johnson et al, 1993[72]; Lamers et al, 2003[87]; Mirrahimi et al, 2015[107]; Rahimi-Bashar et al, 2017[122]; Rinosl et al, 2013[125]). MgSO 4 was shown to decrease S100B levels with little side effects (Hassan et al, 2012[58]).…”

“…Higher need to mechanical ventilation, increase in the length of mechanical ventilation, increase in the risk of sepsis, higher APACHE score, decrease in NIHS score, decrease in serum albumin level and hypokalemia were also reported in these patients (Jiang et al, 2017[71]; Kumar et al, 2015[85]; Mousavi et al, 2004[109], 2010[110]; Muir and Lees, 1995[112]). MgSO 4 cannot improve the strength of respiratory muscles in the critically ill patients under mechanical ventilation (Johnson et al, 1993[72]). Serum Mg level is a key factor determining the outcome of the patients in ICU (Rahimi-Bashar et al, 2017[122]).…”